Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RZL-012 for Submental Fat Reduction
NCT04867434Phase 2Completed
- Sponsor
- Raziel Therapeutics
- Start
- Jun 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Tapencarium in submental fat, sponsored by Raziel Therapeutics. Started Jun 2021; status: completed.
02
Drugs
Tapencarium
03
Conditions
submental fat
Beyond the preview
Go deeper on NCT04867434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04867434.